Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

Background:In a phase I dose-escalation study, regorafenib demonstrated tolerability and antitumour activity in solid tumour patients. The study was expanded to focus on patients with metastatic colorectal cancer (CRC).Methods:Patients received oral regorafenib 60–220 mg daily (160 mg daily in the extension cohort) in cycles of 21 days on, 7 days off treatment. Assessments included toxicity, response, pharmacokinetics and pharmacodynamics.Results:Thirty-eight patients with heavily pretreated CRC (median 4 prior lines of therapy, range 0–7) were enrolled in the dose-escalation and extension phases; 26 patients received regorafenib 160 mg daily. Median treatment duration was 53 days (range 7–280 days). The most common treatment-related toxicities included hand–foot skin reaction, fatigue, voice change and rash. Twenty-seven patients were evaluable for response: 1 achieved partial response and 19 had stable disease. Median progression-free survival was 107 days (95% CI, 66–161). At steady state, regorafenib and its active metabolites had similar systemic exposure. Pharmacodynamic assessment indicated decreased tumour perfusion in most patients.Conclusion:Regorafenib showed tolerability and antitumour activity in patients with metastatic CRC. This expanded-cohort phase I study provided the foundation for further clinical trials of regorafenib in this patient population.

• Publication year

  2012

• Venue

  British Journal of Cancer

• Publication date

  2012-05-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/bjc.2012.153PMID 22568966PMCID 3364125
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

  2012cited by this paper
• 7141 POSTER Phase II Trial of the Oral Multikinase Inhibitor Regorafenib (BAY 73-4506) as First-line Therapy in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)

  2011cited by this paper
• Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

  2011cited by this paper
• NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• National Comprehensive Cancer Network (NCCN) Head and Neck Cancers NCCN Clinical Practice Guidelines in Oncology . 2010.

  2011cited by this paper
• Abstract 1666: Regorafenib (BAY 73-4506): preclinical pharmacology and clinical identification and quantification of its major metabolites

  2010cited by this paper
• Evolving Treatment of Advanced Colorectal Cancer

  2010influential reference
• NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.

  2009cited by this paper
• DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study

  2009cited by this paper
• 7105 Phase II trial of the oral multikinase inhibitor BAY 73–4506 as 1st-line therapy in patients with metastatic or unresectable renal cell cancer (RCC)

  2009cited by this paper
• An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.

  2008cited by this paper
• Gemcitabine and protracted 5-fluorouracil infusion as third-line chemotherapy in refractory colorectal cancer patients.

  2008cited by this paper
• Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

  2007cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Activity of irinotecan, cisplatin and dacarbazine (CPD) combination in previously treated patients with advanced colorectal carcinoma.

  2004cited by this paper
• Bioanalytical Method Validation

  2004cited by this paper
• Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations

  2003cited by this paper

• Structure-Guided Design of Benzothiazole and Benzimidazole-Based Urea Derivatives Curtailing Oncogenic Signaling via Concurrent Inhibition of VEGFR-2, EGFR, and c‑Met

  2026cites this paper
• The Evolving Role of Second- and Third-Generation Tyrosine Kinase Inhibitors in Gastrointestinal Malignancies: Advances in Targeted Therapy with Sunitinib, Regorafenib, and Avapritinib

  2026influential citation
• Synergistic mechanisms and clinical translation of regorafenib combination therapies.

  2026cites this paper
• Fluorine in Pharmaceuticals and Synthetic Strategies for Fluorine-Containing Molecules in Anticancer Drug Discovery: A Review

  2026cites this paper
• Early Higher Plasma Regorafenib Concentration Predicts Shorter PFS in Japanese Patients With mCRC

  2025cites this paper
• Development of new urea derivatives based on isoniazid as antiproliferative agents and apoptosis inducers targeting VEGFR-2 with in-silico ADMET and molecular docking simulation

  2025cites this paper
• Therapeutic Potential of STE20-Type Kinase STK25 Inhibition for the Prevention and Treatment of Metabolically Induced Hepatocellular Carcinoma

  2025cites this paper
• A randomized, open-label, two-period crossover study to evaluate the bioequivalence and food effect between two formulations of regorafenib in healthy adult participants

  2025influential citation
• Recent Advances in dehydroacetic acid-clubbed pyridine conjugates: design, synthesis, characterization, molecular docking investigations and evaluation of anti-cancer efficacy.

  2025cites this paper
• Regorafenib as a potential drug for severe COVID‐19: inhibition of inflammasome activation in mice

  2025cites this paper
• Safety and Efficacy of Regorafenib and 5-Fluorouracil Combination Therapy in Refractory Metastatic Colorectal Cancer After Third-Line Treatment: An Institutional Experience

  2025cites this paper
• Efficacy and safety of regorafenib for the treatment of metastatic colorectal cancer in routine clinical practice: results from a Spanish hospital

  2024cites this paper
• A Comprehensive Review of Targeting RAF Kinase in Cancer Targeting RAF Kinase in Cancer.

  2024cites this paper
• Small molecule-based targeted therapy in liver cancer.

  2024cites this paper
• Biological and computational assessment of new synthesized nicotinamides as potential immunomodulatory VEGFR-2 inhibitors

  2024cites this paper
• From Deep Learning to the Discovery of Promising VEGFR‐2 Inhibitors

  2024cites this paper
• Appropriate dose of regorafenib based on body weight of colorectal cancer patients: a retrospective cohort study

  2023cites this paper
• Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice

  2023cites this paper
• Platform combining statistical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinoma

  2023cites this paper
• Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer

  2023cites this paper
• Defining regorafenib as a senomorphic drug: therapeutic potential in the age-related lung disease emphysema

  2023cites this paper
• Regorafenib prevents the development of emphysema in a murine elastase model

  2023cites this paper
• Targeting accelerated pulmonary ageing to treat chronic obstructive pulmonary disease‐induced neuropathological comorbidities

  2023cites this paper
• Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition.

  2022cites this paper
• Aspirin Synergizes with Regorafenib to Reduce Growth of Colorectal Cancer

  2022cites this paper
• Synthesis, Anticancer Evaluation and Molecular Docking Studies of Isonicotinamide and Diaryl Urea Hybrid Motifs

  2022cites this paper
• Role of anti-angiogenic factors in the pathogenesis of breast cancer: A review of therapeutic potential.

  2022cites this paper
• Modified Benzoxazole-Based VEGFR-2 Inhibitors and Apoptosis Inducers: Design, Synthesis, and Anti-Proliferative Evaluation

  2022cites this paper
• Continuous‐Flow Divergent Lithiation of 2,3‐Dihalopyridines: Deprotolithiation versus Halogen Dance

  2022cites this paper
• RET signaling pathway and RET inhibitors in human cancer

  2022cites this paper
• Synergistic Anti-Angiogenic Effect of Combined VEGFR Kinase Inhibitors, Lenvatinib, and Regorafenib: A Therapeutic Potential for Breast Cancer

  2022cites this paper
• New Series of VEGFR-2 Inhibitors and Apoptosis Enhancers: Design, Synthesis and Biological Evaluation

  2022cites this paper
• 1-[2-(1H-Pyrrole-2-carbonyl)phenyl]-3-(4-methoxyphenyl)urea

  2022cites this paper
• Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors

  2022cites this paper
• Development and validation of a simple and sensitive HPLC method for the determination of related substances in regorafenib tablets

  2022cites this paper
• Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study.

  2022cites this paper
• DDDT_A_344750 587..606

  2022cites this paper
• TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer

  2021cites this paper
• TAS-102 Independent and Combined Therapy in Metastatic Colorectal Cancer

  2021cites this paper
• Identification of Novel Potential VEGFR-2 Inhibitors Using a Combination of Computational Methods for Drug Discovery

  2021cites this paper
• MYO1B enhances colorectal cancer metastasis by promoting the F-actin rearrangement and focal adhesion assembly via RhoA/ROCK/FAK signaling

  2021cites this paper
• 18F-FDG-PET/CT as an imaging biomarker for regorafenib efficacy in metastatic colorectal cancer (JACCRO CC-12)

  2021cites this paper
• Development of a Simple, Precise, and Validated HPLC Method for the Anticancer Drug, Regorafenib: Application to Pharmacokinetics in Rats and Stability Study

  2021cites this paper
• Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies.

  2021cites this paper
• Experience with regorafenib in the treatment of hepatocellular carcinoma

  2021cites this paper
• Efficacy and safety of anlotinib in patients with advanced malignancy: a single-center, single-arm, phase 2 trial

  2021cites this paper
• Diarylureas as Antitumor Agents Diarylureas as Antitumor Agents

  2021cites this paper
• Precision Oncology, Signaling and Anticancer Agents in Cancer Therapeutics.

  2021cites this paper
• Design, synthesis and molecular modeling of new quinazolin-4(3H)-one based VEGFR-2 kinase inhibitors for potential anticancer evaluation.

  2021cites this paper
• Molecularly targeted therapy for advanced gastrointestinal noncolorectal cancer treatment: how to choose? Past, present, future

  2021cites this paper
• Diarylureas as Antitumor Agents

  2021cites this paper
• Detailed electrochemical behavior and thermodynamic parameters of anticancer drug regorafenib and its sensitive electroanalytical assay in biological and pharmaceutical samples

  2021cites this paper
• Cocrystals of regorafenib with dicarboxylic acids: synthesis, characterization and property evaluation

  2021cites this paper
• Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

  2021cites this paper
• Regorafenib outcomes from the population based South Australian Metastatic Colorectal Cancer Registry

  2021cites this paper
• Quantitative Methods for The Trace Level Determination of Potential Genotoxic Impurities in Anti-Cancer Drug, Regorafenib Using Gas Chromatography with Mass Spectrometry (GC-MS)

  2021cites this paper
• Bioequivalence and Pharmacokinetic Evaluation of Two Oral Formulations of Regorafenib: An Open-Label, Randomised, Single-Dose, Two-Period, Two-Way Crossover Clinical Trial in Healthy Chinese Volunteers Under Fasting and Fed Conditions

  2021cites this paper
• Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC

  2021cites this paper
• STABILITY INDICATING METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS QUANTIFICATION OF SORAFENIB AND REGORAFENIB DRUG SUBTANCES BY USING RP-UPLC

  2020cites this paper
• Combination of Apatinib and Transcatheter Arterial Chemotherapy Embolization (TACE) for the Treatment of Liver Metastasis of Gastrointestinal Stromal Tumors: Report of One Rare Case

  2020cites this paper
• Current treatment options for HCC: from pharmacokinetics to efficacy and adverse events in liver cirrhosis.

  2020cites this paper
• The recent advancement of low-dimensional nanostructured materials for drug delivery and drug sensing application: A brief review

  2020cites this paper
• The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma

  2020cites this paper
• A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer

  2020cites this paper
• Differential Pulse Voltammetric Determination of Anticancer Drug Regorafenib at a Carbon Paste Electrode: Electrochemical Study and Density Functional Theory Computations

  2020cites this paper
• Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways

  2020cites this paper
• Regorafenib Regulates AD Pathology, Neuroinflammation, and Dendritic Spinogenesis in Cells and a Mouse Model of AD

  2020cites this paper
• Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial

  2020cites this paper
• Efficacy and safety of regorafenib as beyond second-line therapy in patients with metastatic colorectal cancer: an adjusted indirect meta-analysis and systematic review

  2020cites this paper
• Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake

  2020cites this paper
• Design, synthesis, and biological evaluation of novel 4‐phenoxypyridine derivatives as potential antitumor agents

  2019cites this paper
• Long‐term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review

  2019cites this paper
• Endothelial cells in colorectal cancer

  2019cites this paper
• Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities

  2019cites this paper
• Discovery of arylamide-5-anilinoquinazoline-8-nitro derivatives as VEGFR-2 kinase inhibitors: Synthesis, in vitro biological evaluation and molecular docking.

  2019cites this paper
• Regorafenib Enhances Lethality of Sildenafil and Curcumin in Colorectal Cancer Cells

  2019cites this paper
• The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib

  2019cites this paper
• Comparison of Standard Initial Dose and Reduced Initial Dose Regorafenib for Colorectal Cancer Patients: A Retrospective Cohort Study

  2019cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma

  2019cites this paper
• Discovery of 6‐Arylurea‐2‐arylbenzoxazole and 6‐Arylurea‐2‐arylbenzimidazole Derivatives as Angiogenesis Inhibitors: Design, Synthesis and in vitro Biological Evaluation

  2019cites this paper
• Meta-Analysis of Regorafenib-Associated Adverse Events and Their Management in Colorectal and Gastrointestinal Stromal Cancers

  2019cites this paper
• Synthesis and biological evaluation of novel benzylidene-succinimide derivatives as noncytotoxic antiangiogenic inhibitors with anticolorectal cancer activity in vivo.

  2019cites this paper
• Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies

  2019cites this paper
• Influx and Efflux Transporters Contribute to the Increased Dermal Exposure to Active Metabolite of Regorafenib After Repeated Oral Administration in Mice.

  2019cites this paper
• The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer

  2019influential citation
• Selecting treatment options in refractory metastatic colorectal cancer

  2019cites this paper
• Study Protocol of Regorafenib Escalation for Colorectal Cancer (RECC): A Phase II Multicenter Clinical Trial of the Efficacy and Safety of Regorafenib Dose Escalation Therapy as the Third or Fourth Line Therapy for Unresectable/Recurrent Colorectal Cancer

  2019cites this paper
• Juntendo Medical Journal

  2019cites this paper
• Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging.

  2019cites this paper
• Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402)

  2018cites this paper
• Regorafenib: A Review in Metastatic Colorectal Cancer

  2018cites this paper
• Discovery of novel picolinamide-based derivatives as novel VEGFR-2 kinase inhibitors: synthesis, in vitro biological evaluation and molecular docking.

  2018cites this paper
• Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.

  2018cites this paper
• Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation

  2018cites this paper
• The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma

  2018cites this paper
• Small Molecules in Oncology

  2018cites this paper
• Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a “me too” drug?

  2018cites this paper
• Regorafenib.

  2018cites this paper
• Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer

  2018cites this paper
• The Role Of Cdk8 In Metastatic Growth Of Colon Cancer

  2018cites this paper